Will biotech “castoffs” develop the next blockbuster drugs?, asks a recent Wall Street Journal article ($). The article profiles Speedel Holding AG, and its founder Alice Huxley, who successfully created and developed drug aliskiren as a potential blockbuster—in the privacy of her own home. Big pharma are casting off slow-to-move projects, and small startups, such as Huxley’s own company, are finding opportunities in the rejects.